Major Products
SK bioscience is a leading vaccine company that emerged as a spin-off from SK chemicals in 2018. Prior to the spin-off, SK bioscience selected premium vaccines with high-added value as its primary growth engine. Since then, it has continuously made development efforts, successfully creating Korea’s first trivalent cell culture influenza vaccine in 2015, a quadrivalent cell culture influenza vaccine in 2016, a zoster vaccine in 2017, a varicella vaccine in 2018, and the first homegrown Covid-19 Vaccine SKYCovione in 2022. In addition to premium vaccines, SK bioscience has secured a new pipeline and platform technologies in the fields of basic and therapeutic vaccines. Simultaneously, while expanding its business into biopharmaceuticals, it has established a plan to become a major global vaccine and bio-company.
-
SKYCellflu Trivalent
(Cell-culture-derived influenza vaccine)
In 2015, SKYCellflu Trivalent was the first cell culture-based influenza vaccine developed in South Korea.
It is manufactured in bioreactors without any antibiotics or preservatives, unlike fertile chicken eggs which can be dangerous for people with allergies.
As a cell culture-based vaccine, it acquired the first World Health Organization Pre-Qualification(PQ)
certification.
-
SkyZoster Inj.
(Herpes zoster live attenuated vaccine)
The world’s second and South Korea’s first shingles vaccine(herpes zoster), SKYZoster Inj. is a premium vaccine.
The vaccine is a live attenuated varicella-zoster virus, which has been rigorously proven safe by specialized non-clinical trial institutes, and provided to various countries.
After its launch, the vaccine has become a leading product in meeting the rising demand for herpes zoster treatments.
-
SKYCovione Multi Inj.
(Recombinant protein vaccine for COVID-19)
SKYCovione is South Korea’s first developed recombinant protein-based COVID-19 vaccine.
Additionally, these vaccines can be stored under refrigerated conditions of 2 to 8 degrees Celsius, allowing them to be distributed using the existing vaccine logistics network without the need for thawing or other processes during the administration stage.
-
SKYCellflu Quadrivalent
(Cell-culture-based influenza vaccine)
SKYCellflu Quadrivalent is South Korea’s only and the world’s first cell culture-based quadrivalent influenza vaccine.
Same with SKYCellflu Trivalent, it is manufactured in bioreactors without any antibiotics or preservatives which shortens the production period by 2-3 months and secures production stability comparing to the conventional technique of using fertile chicken eggs.
Based on the WHO Pre-Qualification(PQ), its innovation and reliability have garnered high market shares domestically and globally.
-
SKYVaricella Inj.
(Live Varicella Virus Vaccine)
A chickenpox vaccine, SKYVaricella Inj. was developed with our own bioprocess technology.
Its immunogenicity and safety have been confirmed in a global phase 3 clinical trial conducted in children between 12 months and 12 years at 19 clinical institutions both domestic and abroad.
It received the world's second WHO PQ certification and won the bid for export to Latin America from the Pan American Health Organization (PAHO), an international United Nations organization.
-
SKYTyphoid Multi Inj.
(Typhoid conjugate vaccine, for export)
SKYTyphoid Multi Inj. is a polysaccharide-protein conjugate vaccine developed by conjugating the polysaccharide of typhoid bacteria, which acts as the antigen, to the diphtheria toxin protein (diphtheria toxoid), which acts as a carrier.
Since 2013, SK bioscience jointly developed the vaccine with the International Vaccine Institute(IVI) and Bill & Melinda Gates Foundation. After the completion of development in 2022, we have even obtained a export item license.
It offers higher immunogenicity with a single dose and provides longer-term prevention, thus inoculation for infants and toddlers exposed to poor environment lacking clean water can be effective.
